(Total Views: 398)
Posted On: 12/18/2020 5:27:34 AM
Post# of 36541
GNBT has very limited revenue based on current filings. As far as I know the limited funds rec'd for vaccine covid research isn't going to pay the utilities, legal fees for numerous lawsuits, most of the staff salaries etc. Can't spend it on Altucell which is a big back issue that needs to get closed, Regentys research(possibly tens of millions of dollars) or cancer research(definitely tens of millions of dollars).
Generex has shares and a deal with Oasis. Short of getting Merck or another partner that actually puts $ in the pot for research, the question isn't will we get diluted, it is how much and at what price.
This can change "soon". NGIO's valuation and a successful IPO as GNBT owns 90%ish(for now). That is what I am eager to see.
I don't question Joe's desire to build shareholder value but the reality is money for operations has to come from somewhere.
Generex has shares and a deal with Oasis. Short of getting Merck or another partner that actually puts $ in the pot for research, the question isn't will we get diluted, it is how much and at what price.
This can change "soon". NGIO's valuation and a successful IPO as GNBT owns 90%ish(for now). That is what I am eager to see.
I don't question Joe's desire to build shareholder value but the reality is money for operations has to come from somewhere.
(2)
(0)Scroll down for more posts ▼
